Abstract
The increasing prevalence of obesity among older adults is a significant clinical and public health challenge. In this population, obesity contributes to numerous chronic diseases, functional decline and elevated mortality. This growing concern highlights the urgent need for more effective weight management strategies for older adults. Pharmacologic treatments, particularly GLP-1 receptor agonists and dual agonists, have emerged as promising treatments for weight loss, but their effects remain understudied in older adults. In this article, we discuss the potential musculoskeletal implications associated with the use of weight loss pharmacotherapy among older adults. We emphasize the consequences of lean mass loss, particularly the loss of skeletal muscle mass, which represents a critical determinant of ambulation, physical function and major regulator of metabolic health in older adults. We also describe the adverse risks of weight regain and weight cycling, and the significance of lean mass preservation during weight loss for older individuals. Finally, we identify knowledge gaps associated with safe and effective obesity pharmacotherapy in older adults and emphasize the potential benefits of combining GLP-1 therapies with promyogenic agents, structured exercise, and targeted nutritional interventions for optimizing weight loss quality in this population. These integrated approaches merit further investigation in clinical trials to determine their synergist effects for enhancing body composition while promoting independence, vitality and wellbeing in older adults undergoing pharmacologic weight loss.
Introduction
The rising prevalence of obesity among older adults, now affecting over 40% of individuals aged 65 and older in the United States, represents a significant clinical and public health challenge (; ). In this population, obesity contributes to numerous chronic conditions, including type 2 diabetes, cardiovascular disease, many types of cancers, osteoarthritis, and neurodegenerative disorders, and is independently associated with functional decline, increased disability, greater healthcare utilization, and elevated mortality (; ). This escalating burden highlights the urgent need for more effective weight management strategies for older adults.
Pharmacologic therapies, particularly glucagon-like peptide-1 receptor agonists and newer dual agonists (GLP-1s), have emerged as promising treatments for obesity. These agents induce rapid and substantial weight loss, with accompanying improvements in glycemic control and cardiometabolic outcomes (; ). However, a key limitation of the current evidence base is the underrepresentation of older adults in clinical trials of pharmacologic weight loss therapies. As a result, there is limited understanding of how these medications specifically impact older adults, particularly in relation to their long-term effects on musculoskeletal health, physical functioning and other outcomes vital to maintaining quality of life, independence, and healthspan among older persons.
This article highlights current knowledge gaps associated with the growing use of weight loss medications in older adults and potential strategies for quality weight management. We discuss the consequences of lean mass loss, the adverse implications of weight regain and weight cycling, and the significance of lean mass preservation during weight loss in older individuals. We also identify critical areas for future research and highlight emerging adjunctive or combination strategies that may minimize adverse risks and optimize the effects of GLP-1-induced weight loss approaches among older adults (Table 1).
TABLE 1
| Evidence gaps | Opportunities for future research |
|---|---|
| Older adults, especially those with functional limitations, remain underrepresented in trials of GLP-1 receptor agonists and other weight loss pharmacotherapies | Design and implement randomized trials that intentionally recruit diverse older populations, including those with multimorbidity or reduced physical function |
| Insufficient data on the impact of pharmacologic weight loss on body composition, physical function, and bone health in functionally limited older adults | Incorporate detailed assessments of lean and bone mass, muscle performance, physical function and fall risk in future pharmacotherapy studies |
| Long-term consequences of weight regain and weight cycling following GLP-1 treatment are poorly characterized in older populations | Conduct longer term studies to examine the musculoskeletal and metabolic implications of repeated weight loss and regain |
| Uncertainty about the additive or synergistic effects of combination strategies to mitigate musculoskeletal risk during pharmacologic weight loss | Evaluate multimodal interventions that combine GLP-1 therapy with exercise training, anabolic therapies, and/or targeted nutrition interventions |
Key evidence gaps and future research directions to improve the quality of pharmacologic weight loss in older adults.
Musculoskeletal risks associated with lifestyle weight loss strategies in older adults
Lifestyle-based interventions, including caloric restriction, exercise training, and behavioral support, have demonstrated meaningful short-term benefits for older adults with obesity. These include reductions in fat mass, improved glycemic control, enhanced mobility, and better quality of life (; ; ; ). However, nearly all weight loss strategies, whether intentional or unintentional, are accompanied by loss of lean mass, and particularly the loss of skeletal muscle mass. Skeletal muscle mass is essential not only for physical function and everyday activities () but also as a pivotal regulator of systemic metabolic health. It serves as a primary site for glucose uptake and utilization, influences adipose tissue regulation, and is a major determinant of resting and total energy expenditure (). Consequently, the implications of skeletal muscle loss are particularly important for older adults, who may already be nearing a threshold of vulnerability for musculoskeletal complications such as sarcopenia, frailty, and mobility impairment. Furthermore, reduced appendicular muscle mass and muscle strength are powerful predictors of survival, physical functioning, and independence in older adults (; ; ; ). While low baseline muscle mass is a well-established risk factor for adverse outcomes, emerging evidence suggests that muscle loss occurring during periods of weight change may confer additional, independent risks. For example, findings from the Health ABC study indicate that weight loss in older adults significantly decreases thigh muscle area, independently predicting greater mortality risk (). Therefore, the preservation of skeletal muscle mass should be a central objective in any weight reduction strategy, whether lifestyle-based or pharmacologic.
Other epidemiologic evidence highlights bone loss as another significant musculoskeletal consequence of weight loss in older adults. In the Study of Osteoporotic Fractures, women who lost ≥5% of body weight had a 68% higher risk of hip fracture and a 39% higher risk of non-spine fracture, independent of baseline body composition (). These results were further supported by findings of the Women’s Health Initiative Study, reporting a 65% increased risk of hip fractures with unintentional weight loss ≥5% over an 11-year follow-up in a large cohort of postmenopausal women (). A sub-analysis of the Look AHEAD study found that participants in the lifestyle intervention group lost significantly more bone mineral density (BMD) at the hip, femoral neck, and lumbar spine than controls over 4 years, despite only modest (∼6.5%) weight loss (). These results were further supported by Johnson et al., who reported an increased risk of frailty fracture with long term intentional weight loss over a median 9.6 years follow up period ().
Adverse effects of weight regain and weight cycling
Another critical yet frequently overlooked aspect of obesity treatment in older adults is the pattern and composition of weight regain. Even when weight loss is intentional and initially beneficial, the long-term physiological consequences can vary substantially. Data from the Health ABC study demonstrate that lean mass regained after weight loss is consistently less than the amount originally lost, resulting in an asymmetrical pattern of recovery that favors fat accumulation (). This imbalance may accelerate the development of sarcopenic obesity, a condition characterized by concurrent reductions in muscle mass and increases in adiposity which confers a greater risk for disability, hospitalization, and mortality than either obesity or sarcopenia alone (; ). This pattern of disproportionate fat regain can be further complicated by weight cycling which is defined as repeated episodes of intentional weight loss followed by unintentional weight regain. Lee et al. demonstrated that older adults undergoing repeated weight cycling experienced a net loss of lean mass over time, reinforcing concerns about the cumulative musculoskeletal toll of weight fluctuation in aging populations (). Middle-aged and older adults who experience weight cycling or weight regain after intentional weight loss exhibited greater deficits in muscle performance and other objective measures of physical function compared to those with more stable weight trajectories over an ∼8-year follow-up period (). Furthermore, weight cycling is associated with greater adipose tissue inflammation and insulin resistance (; ), and higher all-cause mortality than a consistently obese state ().
Critical evidence gaps associated with pharmacologic weight loss in older adults
While GLP-1s are emerging as transformative agents in obesity treatment, their impact on body composition, particularly in older adults, remains insufficiently understood. Many pivotal trials primarily enrolled middle-aged adults and either underrepresented older adults or excluded those over the age of 65 altogether, restricting generalizability to the aging population. In addition, most trials to date have prioritized endpoints that focus on the magnitude of total weight loss and cardiometabolic outcomes, with limited focus on the composition of actual weight lost or on functional outcomes of meaningful relevance to older adults. Pooled data suggest that lean mass loss may account for approximately 40%–60% of total weight lost with GLP-1 therapy (). Subgroup analyses from STEP 1 and SURMOUNT-1 indicate that in participants aged ≥65, lean mass accounted for approximately 40% and 26% of total weight lost, respectively (; ; ). While informative, these data are based on small samples and do not adequately capture the functional implications of weight loss in broader, more heterogeneous populations of older adults, and particularly among those who may have multiple comorbidities, or who are at elevated risk for sarcopenia, frailty falls, or other aging-related conditions.
Combination strategies to optimize the quality of pharmacologic weight loss
Given the adverse musculoskeletal risks associated with both lifestyle- and pharmacologically induced weight loss in older adults, growing attention is being directed toward combination strategies aimed at optimizing body composition changes while preserving physical function. Several investigational promyogenic agents (pharmacologic compounds designed to stimulate muscle growth or inhibit muscle catabolism) are emerging as promising in this domain. Bimagrumab, a monoclonal antibody that inhibits activin type II receptors, has been shown to simultaneously decrease fat mass and increase lean mass. In a randomized controlled trial involving older adults with obesity, 48 weeks of bimagrumab treatment led to a 20% reduction in fat mass and a 3.6% increase in lean mass, alongside favorable reduction in hemoglobin A1c (). Other agents such as trevogrumab and garetosmab, targeting myostatin and activin pathways, have demonstrated similar anabolic potential (). Selective androgen receptor modulators, including enobosarm, have also shown promise for preserving lean mass during weight loss. Early-phase trials of enobosarm reported improvements in strength and muscle mass among older adults undergoing cancer-induced muscle wasting (). More recently, the Phase 2Â b QUALITY trial reported that combining enobosarm with semaglutide reduced lean mass loss by 71% and yielded a 27% greater reduction in fat mass compared to semaglutide alone. Notably, this combination also led to superior preservation of stair-climbing power and lower-extremity strength, highlighting its functional benefits.
Exercise remains one of the most effective adjunctive strategies to preserve musculoskeletal health in weight loss clinical trials. Nicklas et al. evaluated the effects of resistance training with and without caloric restriction in older adults (). They found that participants who combined resistance training with caloric restriction experienced superior improvements in mobility, knee strength, and self-reported disability, despite modest losses in lean mass (18%–20% of the total weight lost). These findings were reinforced by a randomized controlled trial by Villareal et al., which compared the effects of aerobic exercise, resistance training, and a combination of both among obese older adults undergoing weight loss (). The study found that while all groups experienced improvements in functional status, the combination of aerobic and resistance training led to the greatest improvements in physical performance, preservation of lean mass, and attenuation of bone loss.
Building on this foundation of evidence from lifestyle-based interventions, recent pharmacologic weight loss trials have evaluated the combination of GLP-1 therapy with exercise training. Lundgren et al. demonstrated that combining exercise with liraglutide resulted in superior maintenance of weight loss, improved physical performance, and greater preservation of muscle mass compared to either intervention alone (). Further supporting this combined approach, a secondary analysis of a randomized clinical trial involving adults with obesity found that the combination of exercise and GLP-1 therapy preserved BMD at the hip, spine, and forearm, despite greater total weight loss (). In contrast, GLP-1 treatment alone was associated with significant reductions in hip and spine BMD compared to either exercise alone or placebo. In a recent review article, Locatelli et al. further endorse the approach of combining GLP-1 therapy with exercise training, specifically emphasizing that resistance training may have significant potential to optimize body composition, preserve lean mass, and mitigate the muscle loss typically observed with pharmacologic therapies (). While the benefits of exercise are well established under controlled conditions, translating these effects into real-world settings can be challenging due to variability in long-term, program accessibility, and sustained engagement, particularly among older adults.
Adjunct nutritional interventions may offer additional support for preserving musculoskeletal health during pharmacologic weight loss in older adults. Campbell et al. emphasize the critical role of dietary protein in maintaining skeletal muscle, highlighting increased protein requirements in older populations due to age-related anabolic resistance (). Beta-hydroxy beta-methylbutyrate (HMB) supplementation has also shown potential for preserving appendicular lean mass and improving physical function during periods of weight loss, particularly when combined with resistance exercise (). Similarly, leucine-enriched protein supplements have shown beneficial effects on muscle protein synthesis in older adults ().
Collectively, these emerging strategies offer an encouraging framework for optimizing the quality of weight loss in older adults - shifting the focus from monotherapies toward integrated, multimodal interventions that combine GLP-1 treatment with promyogenic drugs, structured exercise or targeted nutrition interventions. Combinations of these approaches warrant further investigation in clinical trials to determine whether they produce synergistic benefits for enhancing body composition, preserving lean mass and physical function, and ultimately promoting independence and healthspan in older adults undergoing pharmacologic weight loss.
Summary and future directions
Even modest, intentional weight loss in older adults can lead to unintended musculoskeletal consequences, underscoring the importance of preserving skeletal muscle mass, as a fundamental component of effective obesity treatment in aging populations. Skeletal muscle determines physical functioning and is a major regulator of metabolic health, which provides a strong rationale for combining promyogenic agents with GLP-1-based pharmacologic therapies. However, despite the growing use of GLP-1 pharmacotherapy, there remains a lack of generalizable data on their short or long-term impact on fat-to-lean mass composition, physical function, fall and fracture risk, and other health outcomes in older adults. There is also a distinct need to conduct clinical trials that target older adults at elevated risk for musculoskeletal decline and generate evidence that can inform safe and effective obesity pharmacotherapy in this population. Weight cycling characterized by weight loss followed by weight gain is associated with adverse health outcomes. In this respect, future trials should incorporate more precise body composition measures and physical function endpoints such as strength, power, walking speed, fall risk, and mobility disability. Given the high prevalence of polypharmacy in older populations, future research should also consider the potential risks and cumulative burden associated with combining multiple pharmacologic agents, carefully balancing benefits in body composition and function with overall medication safety and tolerability. Future clinical trials are also needed to better understand the longer-term musculoskeletal consequences of GLP-1 therapy in older adults. The emphasis of GLP-1 therapy among older adults must shift from a singular focus on the magnitude of weight loss to the quality of weight loss–more pertinently defined as the preservation of muscle, bone, physical performance and other outcomes of meaningful importance to the wellbeing of older persons. The combination strategies that integrate GLP-1 pharmacotherapy with promyogenic drugs, exercise training, and nutritional strategies, represent promising avenues for research and clinical translation to ensure that weight loss improves, not compromises, independence, vitality, and wellbeing of older adults.
Statements
Data availability statement
The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding author.
Author contributions
KR: Writing – review and editing, Writing – original draft. SB: Writing – review and editing.
Funding
The author(s) declare that no financial support was received for the research and/or publication of this article.
Conflict of interest
SB reports receiving consulting fees from OPKO, Aditum, Besins and Versanis; and equity interest in FPT and Xyone therapeutics.
The remaining author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.
Generative AI statement
The author(s) declare that no Generative AI was used in the creation of this manuscript.
Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1
AndersonE. K.GutierrezD. A.KennedyA.HastyA. H. (2013). Weight cycling increases T-cell accumulation in adipose tissue and impairs systemic glucose tolerance. Diabetes62 (9), 3180–3188. 10.2337/db12-1076
2
BasariaS.BhasinS. (2012). Targeting the skeletal muscle-metabolism axis in prostate-cancer therapy. N. Engl. J. Med.367 (10), 965–967. 10.1056/NEJMcibr1203160
3
BatsisJ. A.MackenzieT. A.BarreL. K.Lopez-JimenezF.BartelsS. J. (2014). Sarcopenia, sarcopenic obesity and mortality in older adults: results from the national Health and Nutrition Examination Survey III. Eur. J. Clin. Nutr.68 (9), 1001–1007. 10.1038/ejcn.2014.117
4
BeaversK. M.NeibergR. H.HoustonD. K.BrayG. A.HillJ. O.JakicicJ. M.et al (2015). Body weight dynamics following intentional weight loss and physical performance: the look AHEAD movement and memory Study. Obes. Sci. Pract.1 (1), 12–22. 10.1002/osp4.3
5
CampbellW. W.DeutzN. E. P.VolpiE.ApovianC. M. (2023). Nutritional interventions: dietary protein needs and influences on skeletal muscle of older adults. J. Gerontol. A Biol. Sci. Med. Sci.78 (Suppl. 1), 67–72. 10.1093/gerona/glad038
6
CawthonP. M.BlackwellT.CummingsS. R.OrwollE. S.DuchownyK. A.KadoD. M.et al (2021). Muscle mass assessed by the D3-Creatine dilution method and incident self-reported disability and mortality in a prospective observational Study of community-dwelling older men. J. Gerontol. A Biol. Sci. Med. Sci.76 (1), 123–130. 10.1093/gerona/glaa111
7
CrandallC. J.YildizV. O.Wactawski-WendeJ.JohnsonK. C.ChenZ.GoingS. B.et al (2015). Postmenopausal weight change and incidence of fracture: post hoc findings from Women's Health Initiative Observational Study and Clinical Trials. BMJ350, h25. 10.1136/bmj.h25
8
EnsrudK. E.EwingS. K.StoneK. L.CauleyJ. A.BowmanP. J.CummingsS. R.et al (2003). Intentional and unintentional weight loss increase bone loss and hip fracture risk in older women. J. Am. Geriatr. Soc.51 (12), 1740–1747. 10.1046/j.1532-5415.2003.51558.x
9
FakhouriT. H.OgdenC. L.CarrollM. D.KitB. K.FlegalK. M. (2012). Prevalence of obesity among older adults in the United States, 2007-2010. NCHS Data Brief (106), 1–8. Available online at: https://www.cdc.gov/nchs/data/databriefs/db106.pdf.
10
FerrucciL.de CaboR.KnuthN. D.StudenskiS. (2012). Of Greek heroes, wiggling worms, mighty mice, and old body builders. J. Gerontol. A Biol. Sci. Med. Sci.67 (1), 13–16. 10.1093/gerona/glr046
11
FonsecaG.DworatzekE.EbnerN.Von HaehlingS. (2020). Selective androgen receptor modulators (SARMs) as pharmacological treatment for muscle wasting in ongoing clinical trials. Expert Opin. Investig. Drugs29 (8), 881–891. 10.1080/13543784.2020.1777275
12
GuhD. P.ZhangW.BansbackN.AmarsiZ.BirminghamC. L.AnisA. H. (2009). The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Public Health9, 88. 10.1186/1471-2458-9-88
13
HalesC. M.CarrollM. D.FryarC. D.OgdenC. L. (2020). Prevalence of Obesity and Severe Obesity Among Adults: United States, 2017-2018. NCHS Data Brief, 360. 1–8. Available online at: https://www.cdc.gov/nchs/data/databriefs/db360-h.pdf.
14
HeymsfieldS. B.ColemanL. A.MillerR.RooksD. S.LaurentD.PetricoulO.et al (2021). Effect of bimagrumab vs placebo on body fat mass among adults with type 2 diabetes and obesity: a phase 2 randomized clinical trial. JAMA Netw. Open4 (1), e2033457. 10.1001/jamanetworkopen.2020.33457
15
JastreboffA. M.AronneL. J.AhmadN. N.WhartonS.ConneryL.AlvesB.et al (2022). Tirzepatide once weekly for the treatment of obesity. N. Engl. J. Med.387 (3), 205–216. 10.1056/NEJMoa2206038
16
JensenS. B. K.SorensenV.SandsdalR. M.LehmannE. W.LundgrenJ. R.JuhlC. R.et al (2024). Bone health after exercise alone, GLP-1 receptor agonist treatment, or combination treatment: a secondary analysis of a randomized clinical trial. JAMA Netw. Open7 (6), e2416775. 10.1001/jamanetworkopen.2024.16775
17
JohanssonK.NeoviusM.HemmingssonE. (2014). Effects of anti-obesity drugs, diet, and exercise on weight-loss maintenance after a very-low-calorie diet or low-calorie diet: a systematic review and meta-analysis of randomized controlled trials. Am. J. Clin. Nutr.99 (1), 14–23. 10.3945/ajcn.113.070052
18
JohnsonK. C.BrayG. A.CheskinL. J.ClarkJ. M.EganC. M.ForeytJ. P.et al (2017). The effect of intentional weight loss on fracture risk in persons with diabetes: results from the look AHEAD randomized clinical trial. J. Bone Min. Res.32 (11), 2278–2287. 10.1002/jbmr.3214
19
KatsanosC. S.KobayashiH.Sheffield-MooreM.AarslandA.WolfeR. R. (2006). A high proportion of leucine is required for optimal stimulation of the rate of muscle protein synthesis by essential amino acids in the elderly. Am. J. Physiol. Endocrinol. Metab.291 (2), E381–E387. 10.1152/ajpendo.00488.2005
20
KushnerR. F.CalannaS.DaviesM.DickerD.GarveyW. T.GoldmanB.et al (2020). Semaglutide 2.4 mg for the Treatment of obesity: key elements of the STEP Trials 1 to 5. Obes. (Silver Spring)28 (6), 1050–1061. 10.1002/oby.22794
21
LeeJ. S.VisserM.TylavskyF. A.KritchevskyS. B.SchwartzA. V.SahyounN.et al (2010). Weight loss and regain and effects on body composition: the Health, Aging, and Body Composition Study. J. Gerontol. A Biol. Sci. Med. Sci.65 (1), 78–83. 10.1093/gerona/glp042
22
LiN.ChenS.HeY.ChenY.DuanX.HeW.et al (2025). Effects of oral supplementation of beta -hydroxy-beta -methylbutyrate on muscle mass and strength in individuals over the age of 50: a meta-analysis. Front. Nutr.12, 1522287. 10.3389/fnut.2025.1522287
23
LipkinE. W.SchwartzA. V.AndersonA. M.DavisC.JohnsonK. C.GreggE. W.et al (2014). The Look AHEAD Trial: bone loss at 4-year follow-up in type 2 diabetes. Diabetes Care37 (10), 2822–2829. 10.2337/dc14-0762
24
LocatelliJ. C.CostaJ. G.HaynesA.NaylorL. H.FeganP. G.YeapB. B.et al (2024). Incretin-Based weight loss pharmacotherapy: can resistance exercise optimize changes in body composition?Diabetes Care47 (10), 1718–1730. 10.2337/dci23-0100
25
LookM.DunnJ. P.KushnerR. F.CaoD.HarrisC.GibbleT. H.et al (2025). Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes Obes. Metab.27 (5), 2720–2729. 10.1111/dom.16275
26
LundgrenJ. R.JanusC.JensenS. B. K.JuhlC. R.OlsenL. M.ChristensenR. M.et al (2021). Healthy weight loss maintenance with exercise, liraglutide, or both combined. N. Engl. J. Med.384 (18), 1719–1730. 10.1056/NEJMoa2028198
27
NeelandI. J.LingeJ.BirkenfeldA. L. (2024). Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies. Diabetes Obes. Metab.26 (Suppl. 4), 16–27. 10.1111/dom.15728
28
NewmanA. B.LeeJ. S.VisserM.GoodpasterB. H.KritchevskyS. B.TylavskyF. A.et al (2005). Weight change and the conservation of lean mass in old age: the Health, Aging and Body Composition Study. Am. J. Clin. Nutr.82 (4), 872–916. 10.1093/ajcn/82.4.872
29
NewmanA. B.KupelianV.VisserM.SimonsickE. M.GoodpasterB. H.KritchevskyS. B.et al (2006). Strength, but not muscle mass, is associated with mortality in the health, aging and body composition study cohort. J. Gerontol. A Biol. Sci. Med. Sci.61 (1), 72–77. 10.1093/gerona/61.1.72
30
NicklasB. J.ChmeloE.DelbonoO.CarrJ. J.LylesM. F.MarshA. P. (2015). Effects of resistance training with and without caloric restriction on physical function and mobility in overweight and obese older adults: a randomized controlled trial. Am. J. Clin. Nutr.101 (5), 991–999. 10.3945/ajcn.114.105270
31
NicklasB. J.BrinkleyT. E.HoustonD. K.LylesM. F.HugenschmidtC. E.BeaversK. M.et al (2019). Effects of caloric restriction on Cardiorespiratory fitness, fatigue, and disability responses to aerobic exercise in older adults with obesity: a randomized controlled trial. J. Gerontol. A Biol. Sci. Med. Sci.74 (7), 1084–1090. 10.1093/gerona/gly159
32
OhT. J.MoonJ. H.ChoiS. H.LimS.ParkK. S.ChoN. H.et al (2019). Body-Weight fluctuation and incident diabetes mellitus, cardiovascular disease, and mortality: a 16-Year prospective cohort Study. J. Clin. Endocrinol. Metab.104 (3), 639–646. 10.1210/jc.2018-01239
33
ReidK. F.FieldingR. A. (2012). Skeletal muscle power: a critical determinant of physical functioning in older adults. Exerc Sport Sci. Rev.40 (1), 4–12. 10.1097/JES.0b013e31823b5f13
34
RejeskiW. J.BrubakerP. H.GoffD. C.Jr.BearonL. B.McClellandJ. W.PerriM. G.et al (2011). Translating weight loss and physical activity programs into the community to preserve mobility in older, obese adults in poor cardiovascular health. Arch. Intern Med.171 (10), 880–886. 10.1001/archinternmed.2010.522
35
RubinoD.AbrahamssonN.DaviesM.HesseD.GreenwayF. L.JensenC.et al (2021). Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA325 (14), 1414–1425. 10.1001/jama.2021.3224
36
SantanastoA. J.GoodpasterB. H.KritchevskyS. B.MiljkovicI.SatterfieldS.SchwartzA. V.et al (2017). Body composition remodeling and mortality: the health aging and body composition Study. J. Gerontol. A Biol. Sci. Med. Sci.72 (4), 513–519. 10.1093/gerona/glw163
37
StefanakisK.KokkorakisM.MantzorosC. S. (2024). The impact of weight loss on fat-free mass, muscle, bone and hematopoiesis health: implications for emerging pharmacotherapies aiming at fat reduction and lean mass preservation. Metabolism161, 156057. 10.1016/j.metabol.2024.156057
38
VillarealD. T.ApovianC. M.KushnerR. F.KleinS.American Society forN.NaasoT. O. S. (2005). Obesity in older adults: technical review and position statement of the American Society for Nutrition and NAASO, the obesity Society. Obes. Res.13 (11), 1849–1863. 10.1038/oby.2005.228
39
VillarealD. T.ChodeS.ParimiN.SinacoreD. R.HiltonT.Armamento-VillarealR.et al (2011). Weight loss, exercise, or both and physical function in obese older adults. N. Engl. J. Med.364 (13), 1218–1229. 10.1056/NEJMoa1008234
40
VillarealD. T.AguirreL.GurneyA. B.WatersD. L.SinacoreD. R.ColomboE.et al (2017). Aerobic or resistance exercise, or both, in dieting obese older adults. N. Engl. J. Med.376 (20), 1943–1955. 10.1056/NEJMoa1616338
41
WangY.LuoD.LiuJ.SongY.JiangB.JiangH. (2023). Low skeletal muscle mass index and all-cause mortality risk in adults: a systematic review and meta-analysis of prospective cohort studies. PLoS One18 (6), e0286745. 10.1371/journal.pone.0286745
42
WatersD. L.WardA. L.VillarealD. T. (2013). Weight loss in obese adults 65years and older: a review of the controversy. Exp. Gerontol.48 (10), 1054–1061. 10.1016/j.exger.2013.02.005
43
WildingJ. P. H.BatterhamR. L.CalannaS.DaviesM.Van GaalL. F.LingvayI.et al (2021). Once-Weekly semaglutide in adults with overweight or obesity. N. Engl. J. Med.384 (11), 989–1002. 10.1056/NEJMoa2032183
44
ZamboniM.MazzaliG.FantinF.RossiA.Di FrancescoV. (2008). Sarcopenic obesity: a new category of obesity in the elderly. Nutr. Metab. Cardiovasc Dis.18 (5), 388–395. 10.1016/j.numecd.2007.10.002
Summary
Keywords
obesity pharmacotherapy, older adults, musculoskeletal health, lean mass preservation, promyogenic therapy, exercise interventions, multimodality interventions
Citation
Reid KF and Bhasin S (2025) Moving beyond the scale: musculoskeletal risks, evidence gaps and emerging combination strategies to optimize the quality of weight loss pharmacotherapy in older adults. Front. Aging 6:1640030. doi: 10.3389/fragi.2025.1640030
Received
03 June 2025
Accepted
08 October 2025
Published
24 October 2025
Volume
6 - 2025
Edited by
Jim McKenna, Leeds Beckett University, United Kingdom
Reviewed by
Jason Aziz, Tufts Medical Center, United States
Updates
Copyright
© 2025 Reid and Bhasin.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Kieran F. Reid, kfreid@bwh.harvard.edu
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.